Edgewood Management LLC cut its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 99.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,778 shares of the pharmaceutical company's stock after selling 526,225 shares during the period. Edgewood Management LLC's holdings in Vertex Pharmaceuticals were worth $2,498,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds also recently made changes to their positions in the business. E Fund Management Hong Kong Co. Ltd. raised its stake in Vertex Pharmaceuticals by 51.7% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 2,250 shares of the pharmaceutical company's stock worth $1,176,000 after buying an additional 767 shares during the period. Rathbones Group PLC raised its holdings in Vertex Pharmaceuticals by 3.7% during the third quarter. Rathbones Group PLC now owns 1,083 shares of the pharmaceutical company's stock worth $566,000 after acquiring an additional 39 shares in the last quarter. TIAA CREF Individual & Institutional Services LLC boosted its holdings in shares of Vertex Pharmaceuticals by 5.5% in the 3rd quarter. TIAA CREF Individual & Institutional Services LLC now owns 4,164 shares of the pharmaceutical company's stock valued at $2,177,000 after buying an additional 218 shares during the last quarter. Whittier Trust Co. raised its holdings in shares of Vertex Pharmaceuticals by 34.3% in the 3rd quarter. Whittier Trust Co. now owns 1,964 shares of the pharmaceutical company's stock valued at $1,002,000 after purchasing an additional 502 shares during the period. Finally, Mayflower Financial Advisors LLC lifted its position in shares of Vertex Pharmaceuticals by 4.9% in the third quarter. Mayflower Financial Advisors LLC now owns 1,763 shares of the pharmaceutical company's stock valued at $922,000 after buying an additional 82 shares during the last quarter. Institutional investors own 90.96% of the company's stock.
Analyst Upgrades and Downgrades
A number of research analysts have commented on VRTX shares. Morgan Stanley decreased their price objective on Vertex Pharmaceuticals from $665.00 to $660.00 and set an "overweight" rating on the stock in a report on Tuesday, November 3rd. Leerink Partners initiated coverage on shares of Vertex Pharmaceuticals in a report on Monday, September 21st. They issued an "outperform" rating and a $594.00 target price for the company. Barclays raised their price objective on shares of Vertex Pharmaceuticals from $617.00 to $626.00 and gave the company an "overweight" rating in a report on Wednesday, November 4th. JPMorgan Chase & Co. raised their price target on shares of Vertex Pharmaceuticals from $560.00 to $570.00 and gave the stock an "overweight" rating in a report on Tuesday, November 3rd. Finally, Jefferies Financial Group lifted their price objective on shares of Vertex Pharmaceuticals from $633.00 to $640.00 and gave the company a "buy" rating in a research note on Wednesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $596.44.
Check Out Our Latest Stock Analysis on VRTX
Vertex Pharmaceuticals Price Performance
Shares of NASDAQ VRTX opened at $514.75 on Friday. The stock has a fifty day moving average of $522.72 and a 200-day moving average of $485.26. The stock has a market cap of $130.51 billion, a PE ratio of 33.12, a price-to-earnings-growth ratio of 2.85 and a beta of 0.28. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.89 and a current ratio of 2.34. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $412.27 and a fifty-two week high of $568.67.
Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing analysts' consensus estimates of $4.82 by ($0.06). Vertex Pharmaceuticals had a net margin of 30.70% and a return on equity of 21.98%. The business had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter in the previous year, the business earned $4.80 earnings per share. The firm's revenue was up 11.8% on a year-over-year basis. Equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 16.10 earnings per share for the current year.
Insider Transactions at Vertex Pharmaceuticals
In related news, Director Sangeeta N. Bhatia sold 271 shares of the stock in a transaction on Monday, November 16th. The stock was sold at an average price of $547.86, for a total transaction of $148,470.06. Following the sale, the director directly owned 4,653 shares of the company's stock, valued at $2,549,192.58. This trade represents a 5.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Charles Wagner, Jr. sold 15,286 shares of the company's stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $547.87, for a total value of $8,374,740.82. Following the sale, the executive vice president owned 31,764 shares of the company's stock, valued at approximately $17,402,542.68. This trade represents a 32.49% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 16,557 shares of company stock worth $9,071,071. Corporate insiders own 0.20% of the company's stock.
About Vertex Pharmaceuticals
(
Free Report)
Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex's CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.
Featured Articles
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vertex Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.
While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.